Emergent BioSolutions Inc. (NYSE:EBS) announced today that the U.S. Food and Drug Administration (FDA) is allowing Emergent’s Bayview manufacturing facility to resume production of Johnson & Johnson’s (J&J) Covid-19 vaccine bulk drug substance. This resumption of manufacturing follows extensive reviews by FDA, weeks of diligent work, and close coordination with J&J and FDA to execute on Emergent’s quality enhancement plan.
The Storied 25 Year History Behind the Baltimore Biotech Manufacturing Facility Producing COVID-19 Vaccines
Emergent Biosolutions’ vaccine manufacturing plant in Baltimore has been the subject of many headlines this past year for its’ role in producing several COVID-19 Vaccines. However, the history of this facility goes back more than two decades.
COVID-19 Vaccine Drug Substance Manufactured by Emergent BioSolutions Authorized as Part of Johnson & Johnson’s Emergency Use Authorization
Emergent BioSolutions Inc. (NYSE:EBS) today announced that two batches of COVID-19 vaccine manufactured by Emergent BioSolutions at its Baltimore Bayview facility were determined to be suitable for use by the U.S. Food & Drug Administration (FDA) and have been authorized as part of Johnson & Johnson’s Emergency Use Authorization (EUA).
Emergent BioSolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating CHIKV VLP, the Company’s Chikungunya Virus, Virus-Like Particle Vaccine Candidate
Emergent BioSolutions Inc. (NYSE:EBS) announced two-year persistence data from its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus virus-like particle (CHIKV VLP) vaccine candidate in 415 healthy adults.
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
“5 Questions With…” is a weekly BioBuzz series where we reach out to interesting people in the BioHealth Capital Region to share a little about themselves, their work, and maybe something completely unrelated. March is WOMEN’S HISTORY MONTH and BioBuzz will celebrate by featuring Women in the BioHealth industry all month, especially in “5 Questions With…”. This week we continue the series with Destinie Burgan, Upstream Supervisor of Manufacturing, Emergent BioSolutions.
The BioHealth Capital Region (BHCR) had a remarkable 2020, and there is palpable momentum and excitement in the air as we approach the end of Q1 2021. How will the pandemic impact the region’s push to be “Top 3 by 2023?” Where will this significant momentum lead? These questions are yet to be answered.
Emergent Biosolutions Seeks New Talent to Support Global COVID-19 Vaccination Push, Expanding Project Portfolio
Maryland’s leading vaccine manufacturer, Emergent Biosolutions (Emergent), is a critical cog in the vaccine manufacturing and distribution engine as it has multiple COVID-19 vaccine manufacturing partnerships, including partnerships with J&J and AstraZeneca, among others. Emergent also partners with the Biomedical Advanced Research and Development Authority (BARDA), which provided approximately $628.3M in funding to the company as part of Operation Warp Speed.
5 Questions with Doug White, Senior Vice President, Devices Business Unit Head, Emergent BioSolutions
Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women’s Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc.
2020 was a year like no other for BioHealth Capital Region (BCHR) biotechs, and this year is expected to bring substantial growth across many sectors.